Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.50
Bid: 39.00
Ask: 40.00
Change: 0.50 (1.28%)
Spread: 1.00 (2.564%)
Open: 39.00
High: 39.50
Low: 39.00
Prev. Close: 39.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New distribution agreements

23 Sep 2014 07:00

RNS Number : 3099S
Venture Life Group PLC
23 September 2014
 

 

Venture Life Group plc

("Venture Life" or "the Group")

Long-term distribution agreements signed with four new partners

 

Bracknell, UK - 23 September 2014: Venture Life Group plc (AIM: VLG), the international consumer self-care group addressing the needs of the ageing population, announces that it has signed long-term product distribution agreements with four new partners. The agreements give these distributors exclusive rights to sell certain Venture Life products across a total of nine European territories, including Germany. Based on the contractual minimum purchase obligations of the partners, these four agreements combined should deliver minimum annual revenues of €0.24 million in year 1, rising to €0.59 million in year 5, and totalling €5.1 million over the ten year term of the agreements.

 

The agreements are with the following companies:

 

Distributor

Venture Life product

Territories

Expected first revenues for VLG

Valeant

Procto-eze cream

Six, including Germany

H1 2015

Lyfis

Procto-eze cream and cleanser

Iceland

H1 2015

Symphar

Procto-eze cream

Poland

H1 2015

Deltapharma

Original Bioscalin shampoo and capsules

Albania

H1 2015

 

In addition to these agreements, the Group has already signed a further seven product partnering deals during 2014, as well as four extension deals signed with existing partners for additional Venture Life products. The Group now has distribution agreements covering all 14 of its current branded products in a combined 42 territories worldwide, and its unbranded products manufactured by Biokosmes are sold in over 10 countries.

Jerry Randall, Chief Executive Officer of Venture Life, commented:

"We are delighted to broaden further our partner base in Europe, and to see further validation of our model and products through a long term agreement with Valeant, a global top 50 pharmaceutical company. We are delivering increasing benefits from the merger with Biokosmes and are seeing gathering momentum in our branded portfolio as we broaden the distribution base of our branded products. We are particularly pleased with our first distribution deal in Germany, the fourth largest economy in the world and a major European territory".

 

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0)1344 742 870

 

 

Square1 Consulting

David Bick

Mark Longson +44 (0)20 7929 5599

 

 

JW Communications

Julia Wilson +44 (0)7818 430877

 

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its topical development and manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 50 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

About Procto-eze

Procto-eze helps relieve the discomfort caused by haemorrhoids.

 

About Original Bioscalin

Original Bioscalin helps control hair loss, promotes new hair growth and enhances the overall condition of hair.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADLLFLZKFFBBX
Date   Source Headline
11th Nov 201911:33 amRNSUltraDEX wins at the Dental Industry Awards 2019
7th Oct 201910:57 amRNSHolding(s) in Company
20th Sep 20197:00 amRNSHalf-year Report - Amendment
19th Sep 20197:00 amRNSInterim Results
17th Jul 20197:00 amRNSCommercial update
11th Jul 20193:33 pmRNSDirector/PDMR Shareholding
8th Jul 20195:02 pmRNSHolding(s) in Company
25th Jun 20198:44 amRNSDirector/PDMR Shareholding
3rd Jun 201911:36 amRNSResult of AGM
17th May 20194:35 pmRNSPrice Monitoring Extension
1st May 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSFinal Results
26th Mar 20195:17 pmRNSHolding(s) in Company
20th Mar 20197:00 amRNSNotice of Results Update
29th Jan 20197:00 amRNSTrading and Commercial Update
5th Dec 20183:26 pmRNSHolding(s) in Company
5th Dec 20188:12 amRNSHolding(s) in Company
23rd Nov 20187:00 amRNSChange of adviser and directorate update
15th Nov 20187:00 amRNSCommercial update
20th Sep 20187:01 amRNSDirectorate Change
20th Sep 20187:00 amRNSHalf-year Report
16th Aug 20187:00 amRNSTrading update & notice of interim results
13th Aug 201812:17 pmRNSHolding(s) in Company
8th Aug 20182:15 pmRNSHolding(s) in Company
8th Aug 20187:00 amRNSCompletion of Placing and Acquisition
7th Aug 20184:54 pmRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201810:10 amRNSHolding(s) in Company
6th Aug 201811:51 amRNSResult of General Meeting
23rd Jul 20184:00 pmRNSHolding(s) in Company
20th Jul 20187:00 amRNSPlacing, proposed acquisition and notice of GM
20th Jul 20187:00 amRNSAppointment of Joint Broker
19th Jul 20183:38 pmRNSHolding(s) in Company
18th Jun 20187:00 amRNSIncreased distribution of UltraDEX in Boots, UK
4th Jun 20187:00 amRNSLloyds Pharmacy to list UltraDEX in UK
23rd May 201812:29 pmRNSResult of AGM
21st May 20187:00 amRNS'1000 Companies to Inspire Britain' 2018 report
9th May 20187:00 amRNSAlliance Pharma contract expansion and extension
8th May 20182:54 pmRNSHolding(s) in Company
30th Apr 20187:00 amRNSUltraDEX update
17th Apr 20187:00 amRNSDirector/PDMR Shareholding
5th Apr 20187:00 amRNSDirector/PDMR Shareholding
27th Mar 20187:00 amRNSDirector/PDMR Shareholding
26th Mar 20187:00 amRNS2018 LTIP and Grant of Options to PDMRs
22nd Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of analyst & investor results briefings
16th Feb 20187:00 amRNSInvestor presentation
13th Feb 20187:00 amRNSCommerical update
31st Jan 20187:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.